Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05083130 Completed - COVID-19 Clinical Trials

Awake Prone Positioning in Moderate to Severe COVID-19

Start date: March 8, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is comparing vital signs between standard care and prone position groups. Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites. For those randomized to prone position, a special intervention team will visit patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day.

NCT ID: NCT05083117 Withdrawn - Clinical trials for COVID-19 Acute Respiratory Distress Syndrome

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy

Start date: October 30, 2021
Phase: Phase 2
Study type: Interventional

This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability, efficacy, and PK of XW001 (IL-29 analog) inhalation solution. The purpose of this study is to evaluate whether treatment with XW001 reduces the likelihood of worsening disease in patients with severe COVID-19. Hospitalized patients on oxygen therapy by mask or nasal prongs (WHO-OSCI score 4) will be enrolled.

NCT ID: NCT05083104 Not yet recruiting - COVID-19 Patients Clinical Trials

Assessment of the Natural Anticoagulant Profile in Patients With COVID-19

Start date: November 1, 2021
Phase:
Study type: Observational

At the beginning of 2020, coronavirus disease 19 (COVID-19) was declared a pandemic of international concern and an unprecedented challenge for country-specific health care systems . Patients infected with COVID-19 develop from mild, self-limiting respiratory tract illness to severe progressive pneumonia associated with multi-organ failure . In particular, COVID-19 has been shown to exert significant effects on the hematopoietic system and hemostasis

NCT ID: NCT05083065 Completed - COVID-19 Clinical Trials

Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine

MECOVAC-1
Start date: September 10, 2021
Phase:
Study type: Observational

Covid-19 vaccines offered a good opportunity to counteract the spread of Sars-Cov-2 infection among the general population, reducing significantly both morbidity and mortality. Nevertheless, after the first and second doses of vaccination (regardless of the type of vaccine used) several women required gynaecological visits claiming menstrual Irregularities or abnormal uterine bleeding. Considering this anecdotal evidence, a questionnaire was designed to investigate systematically whether menstrual Irregularities or abnormal uterine bleeding occurred in a significant percentage of women undergoing first and second doses of covid-19 vaccination.

NCT ID: NCT05083039 Completed - Clinical trials for Coronavirus Infections

Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19

Start date: May 14, 2020
Phase:
Study type: Observational

Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory infections, including COVID-19

NCT ID: NCT05083026 Recruiting - Covid19 Clinical Trials

Neutralizing Antibody Level After COVID-19 Vaccination

Start date: June 2, 2021
Phase:
Study type: Observational

1. serial of neutralizing antibody at 2, 4, 6, 9, 12 month after COVID-19 vaccination 2. investigate the factors on antibody titer.

NCT ID: NCT05083013 Not yet recruiting - COVID-19 Clinical Trials

Diabetes In Relation to Hospitalized COVID-19 Patents At Assiut University Hospital

Start date: November 1, 2021
Phase:
Study type: Observational

Coronavirus disease (COVID-19), a global pandemic affecting the whole world and taking the lives of millions. The majority of fatalities occur in the elderly specially in the presence of chronic diseases such as diabetes mellitus (DM), hypertension, obesity, cardiovascular disease, chronic kidney disease and cancer.

NCT ID: NCT05083000 Recruiting - Clinical trials for COVID-19 Respiratory Infection

Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care

Start date: August 16, 2021
Phase: Phase 1
Study type: Interventional

The primary objective of the phase 1 trial is to identify a dose of topotecan that will be safe to take forward into a Phase 2 trial, with no unexpected toxicities or drug-drug interactions with standard therapy for COVID-19. The investigators hypothesise that a single dose of low-dose Topotecan will blunt the expression of inflammatory genes in patients with moderate COVID-19, without cytotoxic side effects.

NCT ID: NCT05082727 Recruiting - COVID-19 Clinical Trials

Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)

Start date: July 1, 2021
Phase: Phase 2
Study type: Interventional

The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus. The reported symptoms vary from fever or chills, cough, shortness of breath, to muscle aches, headaches, loss of taste or smell. The capsule KOVIR is a product based on the traditional medicine which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine.

NCT ID: NCT05082714 Completed - COVID-19 Clinical Trials

Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

Start date: October 20, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether baricitinib is non-inferior to tocilizumab in severe COVID-19.